

March 11, 2002

1900 K STREET, N.W. WASHINGTON, D.C. 20006-1109

TEL 202 • 955 • 1500 FAX 202 • 778 • 2201

DI RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

In re Patent Application of:

Attorney Docket No.:

59866.000002

Mads N. HOLTEN-ANDERSEN et al.

Application No.: 09/546,573

Group Art Unit: 1642

Filed: April 10, 2000

Examiner:

RAWLINGS, S.

Title:

TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1)

AS A CANCER MARKER

Commissioner for Patents Washington, DC 20231

Transmitted herewith is an amendment in the above-identified application. Fees have been calculated as shown below:

		CLA	IMS AS AMENDE	D	****		T
		Claims Remaining After Amendment	Highest Number Previously Paid For	Extra	R: Large Entity	Small Entity	Amount
Number of Claims in Excess of 20		35	37	0	\$ 18.00	\$ 9.00	\$ 0.00
Independent Claims in Excess of 3		9	9	0	\$ 84.00	\$ 42.00	\$ 0.00
First Presentation of Multiple Dependent Claims			·	-	\$ 280.00	\$ 140.00	\$ 0.00
Extension Fee:	a) One Monthb) Two Monthc) Three Monthd) Four Monthe) Five Month	hs s.			\$ 110.00 \$ 400.00 \$ 920.00 \$1440.00 \$1960.00	\$ 55.00 \$ 200.00 \$ 460.00 \$ 720.00 \$ 980.00	\$55.00 \$ 0.00 \$ 0.00 \$ 0.00 \$ 0.00
Other:							\$ 0.00
TOTAL FEE DUE							\$55.00

	No additional fee is required. A check in the amount of \$ 55.00 is attached. Charge \$ to Deposit Account No. 50-0206. Charge any additional fees or credit any overpayment to Deposit Account No. 50-0206.	
□	Small Entity Status Claim: is hereby requested. is of record in this application. Respectfully submitted,	

Registration No. 28.562 ATLANTA AUSTIN BANGKOK BRUSSELS CHARLOTTE DALLAS HONG KNOXVILLE LONDON MCLEAN MIAMI NEW YORK NORFOLK RALEIGH RICHMOND WARSAW WASHINGTON WASHINGTON 276815v1

Copied from 100309/2 on 01-03-2004

Attorney Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mads N. HOLTEN-ANDERSEN et al.

Group Art Unit: 164

Application No.: 09/546,573

PECEIVE CENTER 1600/2900 Examiner: RAWLINGS,

Filed: April 10, 2000

For:

TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES

TYPE-1 (TIMP-1) AS A CANCER MARKER

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents Washington, DC 20231

Sir:

Responsive to the Office Action of November 9, 2001, a one month extension of time having been obtained, please amend the patent application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

I. On page 27, lines 1 - 3, please delete the paragraph and replace it with following replacement paragraph:

The median TIMP-1 level in plasma from healthy donors was 88.6 μg/L with a range of 51.0-156.2 μ g/L. There was a highly significant statistical difference in the total plasma TIMP-1 values between the colorectal cancer patients and the healthy blood donors.

)3/14/2002 ADSMAN1 00000108 09546573

)1 FC:215

55.00 OP